MEDICAL MARIJUANA, INC. PORTFOLIO COMPANY AXIM BIOTECH BEGINS PK/PD STUDIES WITH CANCHEW PLUS CBD GUM FOR IBS SYMPTOMS IN SUFFERING PATIENTS
Medical Marijuana, Inc. (OTC: MJNA) today announced that its portfolio company AXIM® Biotechnologies, Inc. (AXIM® Biotech ) (OTC:AXIM) has begun pharmacokinetic/pharmacodynamics (PK/PD) studies with its CanChew Plus® Gum, the first CBD hemp oil chewing gum, to ascertain the potential for a reduction of irritable bowel syndrome (IBS) symptoms in patients.
Wageningen University in the Netherlands is conducting the PK/PD studies, and the single dose study on 10 mg of cannabidiol (CBD) and 30 mg of CBD will determine the concentration of CBD in the blood after chewing one CanChew Plus® Gum for thirty minutes, which will determine the administered patient dose for AXIM® Biotech’s Phase II trials.
“We congratulate the AXIM team on reaching another major milestone in the Company’s continued efforts to research new solutions using cannabinoid-based drugs,” said Dr. Stuart Titus, CEO of Medical Marijuana, Inc. "We are very excited about the new formulation of CanChew Plus, which we feel will offer superior bioavailability versus our prior rendition of CanChew."
"Further, there is currently no known cure on the market for IBS, yet we believe this novel approach will offer hope for symptom reduction to this group of patients. Medical Marijuana, Inc. offers our full support as investors in AXIM Biotech. Our joint efforts / AXIMs efforts continue to push forward with research regarding new cutting-edge solutions, not only for IBS, but for IBD and Crohn’s disease as well.”
AXIM® Biotech’s founders are also the inventors of CanChew ® , which is the world’s first patented controlled-release cannabinoid chewing gum containing 10 mg of CBD procured from the industrial hemp plant – and AXIM® also holds the exclusive rights, via license agreement, to market and distribute CanChew® Gum and CanChew Plus® around the world.
Public Relations Contact:
Chief Executive Officer
P. 888-829- 0070
Corporate Business Contact:
Nicholas R. Massalas
Director of Business Development
Medical Marijuana, Inc.
OTC Symbol: MJNA
Toll Free: 888-OTC- MJNA (888-682- 6562 )
Investor Relations Contact:
Toll Free: (877) 964.6463
Office/Direct: (858) 264-6500
About Medical Marijuana, Inc.
Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For details on Medical Marijuana, Inc.’s portfolio and investment companies, visit www.medicalmarijuanainc.com .
About AXIM ®
AXIM® Biotechnologies, Inc. (OTC: AXIM) is an innovative biotechnology Company focusing on research, development and production of pharmaceutical, nutraceutical and cosmetic products where we prioritize the well-being of our customers while embracing a solid fiscal strategy. For more information, visit the Company website at www.AXIMBiotech.com .
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.
FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE
These statements have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease.
Medical Marijuana Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). These companies do grow, sell, and distribute hemp-based products and are involved with the federally legal distribution of medical marijuana-based products within certain international markets. Cannabidiol is a natural constituent of hemp oil.